Connective Tissue Disease Treatment Global Market Report 2026
상품코드:1951649
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
결합조직질환 치료 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 245억 5,000만 달러에서 2026년에는 261억 달러로, CAGR 6.3%로 확대될 것으로 예상됩니다. 지난 몇 년간 성장 요인으로는 생물학적 제제의 공급 제한, 기존 DMARD에 대한 의존도, 자가면역결합조직질환의 유병률 증가, 병원 기반 치료 도입 확대, 질병 관리 프로그램에 대한 인식 개선 등을 꼽을 수 있습니다.
결합조직질환 치료 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 329억 7,000만 달러에 달하고, CAGR은 6.0%가 될 전망입니다. 예측 기간 동안 성장 요인으로는 표적형 합성 DMARD 및 JAK 억제제 개발, 생물학적 제제 및 면역억제제에 대한 투자 증가, 재택 및 외래 치료 시설의 확대, 맞춤형 의료 및 환자 중심 치료에 대한 집중 강화, 디지털 헬스 및 원격의료 솔루션의 통합 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 생물학적 제제 및 표적 치료제의 도입 증가, 맞춤형 치료 접근 방식에 대한 선호도 증가, 재택 및 외래 치료 환경의 확대, 경구 및 주사제 약물전달에 대한 수요 증가, 조기 진단 및 질병 관리 프로그램에 대한 관심 증가 등을 꼽았습니다.
자가면역질환의 발생률 증가는 향후 몇 년 동안 결합조직질환 치료 시장의 성장을 견인할 것으로 예상됩니다. 자가면역질환은 면역체계가 인체의 건강한 조직과 기관을 잘못 공격하는 상태를 말합니다. 자가면역질환의 발생률 증가는 주로 유전적 소인(면역계 기능 장애에 대한 감수성 증가)과 감염, 식습관, 스트레스, 독소 노출과 같은 환경적 요인(이러한 상태를 유발하거나 악화시키는)의 복합적인 영향에 기인하는 것으로 알려져 있습니다. 결합조직질환 치료는 염증과 조직 손상을 유발하는 면역체계의 근본적인 이상을 해결함으로써 자가면역질환의 관리를 돕고, 이를 통해 루푸스, 류마티스관절염, 강직성피부염 등의 질환을 앓고 있는 환자들의 증상 완화, 질병 진행 지연, 삶의 질 향상에 도움을 줄 수 있습니다. 예를 들어, 호주의 비영리 단체인 'Arthritis Australia'에 따르면 2024년 2월 기준 2025년에는 약 56만 2,378명의 호주인이 류마티스 관절염을 앓고 있는 것으로 추정되며, 이는 같은 해 전체 관절염 환자의 14%를 차지할 것으로 예상하고 있습니다. 2040년까지 이 수치는 33% 증가하여 74만 8,721명에 달할 것으로 예측되며, 이는 2025년 대비 18만 6,343명의 환자가 증가할 것으로 예상됩니다. 따라서 자가면역질환의 증가 추세는 결합조직질환 치료 시장의 성장에 기여하고 있습니다.
결합조직질환 치료 시장에서 사업을 전개하고 있는 주요 기업들은 임상 연구개발을 중시하고 동종 CAR-NK 세포 치료제 등 혁신적인 치료법을 도입하여 효과 향상과 자가면역질환의 미충족 수요에 대응하기 위해 노력하고 있습니다. 동종 CAR-NK 세포 치료는 건강한 공여자의 자연살해세포를 유전자 조작하여 키메라 항원 수용체(CAR)를 도입하여 질병 원인세포를 표적, 제거하는 기술입니다. 이 방법은 자가면역질환에 관여하는 유해한 B세포를 제거하는 면역기능을 강화하여 기존 세포 치료에 비해 안전하고 접근성이 높은 대안이 될 수 있습니다. 예를 들어, 2024년 7월, 미국에 본사를 둔 임상 단계의 바이오 기업 Nkarta는 루푸스 신염 치료를 위한 동종 CAR-NK 세포 치료제 NKX019를 평가하는 Ntrust-1 임상을 시작했으며, 전신성 경화증, 특발성 염증성 근육질환, ANCA 관련 혈관염에 대한 또 다른 임상(Ntrust-2)을 진행하기 위해 미국 식품의약국(FDA)의 승인을 받았습니다. ANCA 관련 혈관염을 대상으로 한 별도의 임상(Ntrust-2)을 미국 식품의약국(FDA)의 승인을 획득했습니다. 이러한 노력은 CD19를 발현하는 B세포를 선택적으로 표적으로 하는 유전자 변형 NK세포 치료제의 안전성, 접근성, 유효성을 향상시켜 자가면역질환 관리의 중요한 미충족 수요를 충족시키는 것을 목표로 하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 시장에서 세계의 총 잠재 시장 규모(TAM)
제9장 시장 세분화
제10장 지역별, 국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자 환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업과 혁신적 기업
제38장 세계의 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
KSM
영문 목차
영문목차
Connective tissue disease treatment involves the medical management of a range of autoimmune and inflammatory disorders that impact the body's connective tissues, including joints, skin, muscles, and internal organs. The goal of treatment is to reduce inflammation, regulate immune system activity, alleviate symptoms such as pain and fatigue, and prevent disease progression and organ damage.
The main drug classes used in the treatment of connective tissue diseases include anti-inflammatory drugs, immunosuppressants, biologics and targeted therapies, disease-modifying anti-rheumatic drugs (DMARDs), and others. Anti-inflammatory drugs are medications that help decrease inflammation, pain, and swelling by inhibiting the body's inflammatory response and are widely used in managing connective tissue disorders. These drugs are applied across various disease types, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), scleroderma, dermatomyositis, mixed connective tissue disease (MCTD), polymyositis, Sjogren's syndrome, vasculitis, and antiphospholipid syndrome (APS). They are administered through oral, injectable, and topical routes and are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies. These treatments are utilized in different end-user settings, including hospitals, clinics, and home care environments.
Tariffs have affected the connective tissue disease treatment market by increasing costs for imported biologics, immunosuppressants, and advanced drug delivery systems. Segments such as biologics and targeted therapy drugs are particularly impacted, with Asia-Pacific regions including India and China facing notable import duties. This has led to higher treatment costs and supply chain delays. On the positive side, tariffs are encouraging local manufacturing, boosting domestic production capabilities, and driving innovation in cost-effective therapies.
The connective tissue disease treatment market research report is one of a series of new reports from The Business Research Company that provides connective tissue disease treatment market statistics, including connective tissue disease treatment industry global market size, regional shares, competitors with a connective tissue disease treatment market share, detailed connective tissue disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the connective tissue disease treatment industry. This connective tissue disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The connective tissue disease treatment market size has grown strongly in recent years. It will grow from $24.55 billion in 2025 to $26.1 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to limited availability of biologic therapies, reliance on conventional dmards, growing prevalence of autoimmune connective tissue diseases, increasing hospital-based treatment adoption, awareness of disease management programs.
The connective tissue disease treatment market size is expected to see strong growth in the next few years. It will grow to $32.97 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to development of targeted synthetic dmards and jaks, rising investment in biologics and immunosuppressants, expansion of homecare and outpatient treatment facilities, increasing focus on personalized medicine and patient-centric care, integration of digital health and telemedicine solutions. Major trends in the forecast period include rising adoption of biologics and targeted therapies, increasing preference for personalized treatment approaches, expansion of homecare and outpatient treatment settings, growing demand for oral and injectable drug delivery, focus on early diagnosis and disease management programs.
The increasing incidence of autoimmune diseases is anticipated to drive the growth of the connective tissue disease treatment market in the coming years. Autoimmune diseases are conditions in which the immune system mistakenly attacks healthy tissues and organs within the body. The rising occurrence of autoimmune disorders is largely attributed to a combination of genetic predisposition, which increases susceptibility to immune system dysfunction, and environmental influences such as infections, dietary habits, stress, and exposure to toxins that can trigger or aggravate these conditions. Connective tissue disease treatments help manage autoimmune disorders by addressing underlying immune system abnormalities responsible for inflammation and tissue damage, thereby reducing symptoms, slowing disease progression, and enhancing overall quality of life for patients affected by conditions including lupus, rheumatoid arthritis, and scleroderma. For instance, in February 2024, according to Arthritis Australia, an Australia-based non-profit organization, an estimated 562,378 Australians are projected to be living with rheumatoid arthritis in 2025, representing 14% of all arthritis cases that year. By 2040, this figure is expected to increase by 33% to 748,721 individuals, reflecting an additional 186,343 people living with rheumatoid arthritis compared with 2025. Therefore, the rising incidence of autoimmune diseases is contributing to the growth of the connective tissue disease treatment market.
Major companies operating in the connective tissue disease treatment market are emphasizing clinical research and development to introduce innovative therapies, such as allogeneic CAR-NK cell treatments, aimed at improving effectiveness and addressing unmet medical needs in autoimmune conditions. Allogeneic CAR-NK cell therapy involves the use of natural killer cells derived from healthy donors that are genetically engineered with chimeric antigen receptors to target and eliminate disease-causing cells. This approach enhances the immune system's ability to remove harmful B cells involved in autoimmune diseases and offers a potentially safer and more accessible alternative to traditional cell-based therapies. For instance, in July 2024, Nkarta Inc., a US-based clinical-stage biotechnology company, initiated the Ntrust-1 clinical trial to assess NKX019, an investigational allogeneic CAR-NK cell therapy, for the treatment of lupus nephritis, and received US Food and Drug Administration clearance to begin a separate trial (Ntrust-2) targeting systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis. These efforts aim to address critical unmet needs in autoimmune disease management by enhancing the safety, accessibility, and efficacy of genetically engineered NK cell therapies that selectively target CD19-expressing B cells.
In October 2023, Amgen Inc., a US-based biopharmaceutical company, acquired Horizon Therapeutics plc for $27.8 billion. Through this acquisition, Amgen sought to expand its footprint in the rare and autoimmune disease markets by integrating Horizon Therapeutics' portfolio of high-growth biologic therapies, including Tepezza, Krystexxa, and Uplizna. This strategic move strengthens Amgen's development pipeline, diversifies revenue streams, and reinforces its leadership position in specialty therapeutics. Horizon Therapeutics plc is an Ireland-based biopharmaceutical company focused on developing treatments for Sjogren's syndrome and rheumatoid arthritis.
Major companies operating in the connective tissue disease treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline (GSK) PLC, Eli Lilly and Company, Amgen Inc., Biogen Inc., Vertex Pharmaceuticals, UCB S.A., Hikma Pharmaceuticals PLC, Innovent Biologics Inc., RemeGen Co. Ltd, Kymera Therapeutics, Adicet Bio, Equillium Inc.
North America was the largest region in the connective tissue disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the connective tissue disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the connective tissue disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The connective tissue disease treatment market includes revenues earned by entities by providing services such as medication administration, physical rehabilitation, patient education, genetic counselling, long-term disease monitoring, and laboratory testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The connective tissue disease treatment market also includes sales of monoclonal antibodies, biologic agents, and corticosteroids. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Connective Tissue Disease Treatment Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses connective tissue disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for connective tissue disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The connective tissue disease treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Drug Class: Anti-Inammatory Drugs; Immunosuppressants; Biologics And Targeted Therapy; Disease-Modifying Anti-Rheumatic Drugs (DMARDs); Other Drug Classes
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
4.2.1 Rising Adoption Of Biologics And Targeted Therapies
4.2.2 Increasing Preference For Personalized Treatment Approaches
4.2.3 Expansion Of Homecare And Outpatient Treatment Settings
4.2.4 Growing Demand For Oral And Injectable Drug Delivery
4.2.5 Focus On Early Diagnosis And Disease Management Programs
5. Connective Tissue Disease Treatment Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Clinics
5.3 Homecare Settings
5.4 Specialty Treatment Centers
5.5 Research Institutions
6. Connective Tissue Disease Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Connective Tissue Disease Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Connective Tissue Disease Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Connective Tissue Disease Treatment Market Size, Comparisons And Growth Rate Analysis
7.3. Global Connective Tissue Disease Treatment Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Connective Tissue Disease Treatment Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Connective Tissue Disease Treatment Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9.3. Global Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Oral, Injectable, Topical
9.4. Global Connective Tissue Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.7. Global Connective Tissue Disease Treatment Market, Sub-Segmentation Of Immunosuppressants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.8. Global Connective Tissue Disease Treatment Market, Sub-Segmentation Of Biologics And Targeted Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.10. Global Connective Tissue Disease Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Connective Tissue Disease Treatment Market
12.1. China Connective Tissue Disease Treatment Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Connective Tissue Disease Treatment Market
13.1. India Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Connective Tissue Disease Treatment Market
14.1. Japan Connective Tissue Disease Treatment Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Connective Tissue Disease Treatment Market
15.1. Australia Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Connective Tissue Disease Treatment Market
16.1. Indonesia Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Connective Tissue Disease Treatment Market
17.1. South Korea Connective Tissue Disease Treatment Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Connective Tissue Disease Treatment Market
19.1. South East Asia Connective Tissue Disease Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Connective Tissue Disease Treatment Market
20.1. Western Europe Connective Tissue Disease Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Connective Tissue Disease Treatment Market
21.1. UK Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22.1. Germany Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Connective Tissue Disease Treatment Market
23.1. France Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24.1. Italy Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25.1. Spain Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Connective Tissue Disease Treatment Market
26.1. Eastern Europe Connective Tissue Disease Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Connective Tissue Disease Treatment Market
27.1. Russia Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Connective Tissue Disease Treatment Market
28.1. North America Connective Tissue Disease Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Connective Tissue Disease Treatment Market
29.1. USA Connective Tissue Disease Treatment Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Connective Tissue Disease Treatment Market
31.1. South America Connective Tissue Disease Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Connective Tissue Disease Treatment Market
32.1. Brazil Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Connective Tissue Disease Treatment Market
33.1. Middle East Connective Tissue Disease Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Connective Tissue Disease Treatment Market
34.1. Africa Connective Tissue Disease Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Connective Tissue Disease Treatment Market Regulatory and Investment Landscape
36. Connective Tissue Disease Treatment Market Competitive Landscape And Company Profiles
